Accepted for Publication: August 5, 2013.
Published Online: May 14, 2014. doi:10.1001/jamasurg.2013.4332.
Study concept and design: Fallon, Potemkin, Gura, Puder.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Fallon, Mitchell, Puder.
Critical revision of manuscript for important intellectual content: All authors.
Statistical analysis: Mitchell.
Obtained funding: Fallon, Nehra.
Administrative, technical, or material support: Potemkin, O’Loughlin, Gura.
Study supervision: Fallon, Gura, Puder.
Conflict of Interest Disclosures: A license agreement for the use of fish oil–based lipid emulsion (Omegaven) has been signed by Boston Children’s Hospital and Fresenius Kabi, and a patent has been submitted by Boston Children’s Hospital on behalf of Drs Gura and Puder. No other disclosures were reported.
Funding/Support: This study was funded by the Children’s Hospital Surgical Foundation and the Vascular Biology Program within Boston Children’s Hospital (Drs Fallon, Nehra, and Puder and Mss Potemkin and O’Loughlin); by the Joshua Ryan Rappaport Fellowship (Dr Fallon); and by grant T32DK007754-12 from the National Institutes of Health (Dr Nehra).
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Previous Presentation: An abstract of this manuscript was presented at the 93rd Annual Meeting of the New England Surgical Society; September 22, 2012; Rockport, Maine.
Correction: This article was corrected on May 29, 2014, to fix the subtitle.